Abstract | PURPOSE: METHODS: Here, we evaluated ER, PR, AR, and GR expression, using immunohistochemistry, in a cohort of 169 breast cancer patients and correlated these findings with clinical and pathological parameters. RESULTS: We found that AR is more frequently expressed and at higher levels in the ER+PR- subset compared to ER+PR+ tumors. There were no significant differences in GR expression between tumor subsets. Moreover, most luminal tumors also expressed either AR or GR and most basal tumors were also negative for AR and GR. CONCLUSION: These data suggest that targeting AR in ER+PR- tumors may represent a promising therapeutic alternative in hormonal refractory tumors.
|
Authors | Ximena García, Andrés Elía, Lucrecia Galizzi, María May, Eunice Spengler, Paula Martínez Vázquez, Javier Burruchaga, Hugo Gass, Claudia Lanari, Caroline A Lamb |
Journal | Breast cancer research and treatment
(Breast Cancer Res Treat)
Vol. 180
Issue 1
Pg. 257-263
(Feb 2020)
ISSN: 1573-7217 [Electronic] Netherlands |
PMID | 31950383
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Receptors, Androgen
- Receptors, Estrogen
- Receptors, Progesterone
|
Topics |
- Adult
- Aged
- Biomarkers, Tumor
- Breast Neoplasms
(diagnosis, genetics, metabolism)
- Cluster Analysis
- Female
- Gene Expression
- Gene Frequency
- Humans
- Immunohistochemistry
- Middle Aged
- Neoplasm Grading
- Neoplasm Staging
- Receptors, Androgen
(genetics, metabolism)
- Receptors, Estrogen
- Receptors, Progesterone
|